Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Raymond Couric Wadlow

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1959-5406; OpenAlex author ID A5072140815. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
87
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 13

  1. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.08.034↗
  2. Universal Genetic Testing for Pancreatic Cancer: Closing the Gap on a Missed Opportunity. First author DOI 10.1200/op-25-00154↗
  3. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Co-author DOI 10.1093/oncolo/oyaf007↗
  4. Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic… Co-author DOI 10.1200/oa-25-00099↗
  5. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  6. Quantitative proteomic analysis of HER2 protein expression in PDAC tumors. Co-author DOI 10.1186/s12014-024-09476-7↗
  7. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  8. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Last author DOI 10.1158/1940-6207.capr-22-0529↗
  9. A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0440↗
  10. Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo.2017.06.06↗
  11. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  12. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable … Co-author DOI 10.1016/j.ijrobp.2014.03.034↗
  13. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Co-author DOI 10.1002/cncr.26633↗

Closest collaborators

The 25 strongest of 87 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shenin A. Sanoba · 2 shared papers, 2024–2026 · strength 0.77
  2. Jessica N. Everett · 3 shared papers, 2023–2026 · strength 0.48
  3. Bryson W. Katona · 3 shared papers, 2023–2026 · strength 0.48
  4. Diane M. Simeone · 3 shared papers, 2023–2026 · strength 0.48
  5. Randall E. Brand · 3 shared papers, 2023–2026 · strength 0.48
  6. Sonia S. Kupfer · 3 shared papers, 2023–2026 · strength 0.48
  7. Aimee Lee Lucas · 3 shared papers, 2023–2026 · strength 0.48
  8. Salvatore Paiella · 3 shared papers, 2023–2026 · strength 0.48
  9. George Zogopoulos · 3 shared papers, 2023–2026 · strength 0.48
  10. Fay Kastrinos · 3 shared papers, 2023–2026 · strength 0.48
  11. Rosalie C. Sears · 2 shared papers, 2024–2026 · strength 0.36
  12. Erkut Hasan Borazanci · 2 shared papers, 2020–2026 · strength 0.34
  13. Aaron J. Grossberg · 2 shared papers, 2023–2024 · strength 0.25
  14. James M. Lindberg · 2 shared papers, 2023–2024 · strength 0.25
  15. Kasmintan A. Schrader · 2 shared papers, 2023–2024 · strength 0.25
  16. Teresa A. Brentnall · 2 shared papers, 2023–2024 · strength 0.25
  17. Andrew M. Lowy · 2 shared papers, 2023–2024 · strength 0.25
  18. James J. Farrell · 2 shared papers, 2023–2024 · strength 0.25
  19. Elena M. Stoffel · 2 shared papers, 2023–2024 · strength 0.25
  20. Daniel C. Chung · 2 shared papers, 2023–2024 · strength 0.25
  21. Yan Bi · 2 shared papers, 2023–2024 · strength 0.25
  22. Jennifer B. Permuth · 2 shared papers, 2023–2024 · strength 0.25
  23. Julie Earl · 2 shared papers, 2023–2024 · strength 0.25
  24. Norma Alonzo Palma · 1 shared paper, 2026 · strength 0.22
  25. Lisa A. Ford · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.